Anti-myostatin antibodies
A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing hone density, or for the treatment of various disorders in mammalian and avian species.
1. A monoclonal antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein said LCVR comprises:
a) a peptide at CDRL1 with SEQ ID NO: 27, 28 or 29
b) a peptide at CDRL2 with SEQ ID NO: 30, and
c) a peptide at CDRL3 with SEQ ID NO: 58,
and wherein said HCVR comprises:
a) a peptide at CDRH1 with SEQ ID NO: 59,
b) a peptide at CDRH2 with SEQ ID NO: 60, and
c) a peptide at CDRH3 with SEQ ID NO: 61.
2. The antibody of claim 1 , wherein the antibody is a full-length antibody, a substantially intact antibody, a Fab fragment, a F(ab′)2 fragment or a single chain Fv fragment.
3. A monoclonal antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein said LCVR comprises:
a) a peptide at CDRL1 with SEQ ID NO: 27,
b) a peptide at CDRL2 with SEQ ID NO: 30, and
c) a peptide at CDRL3 with SEQ ID NO: 31,
and wherein said HCVR comprises:
a) a peptide at CDRH1 with SEQ ID NO: 37,
b) a peptide at CDRH2 with SEQ ID NO: 43, and
c) a peptide at CDRH3 with SEQ ID NO: 48.
4. The antibody of claim 3 , wherein the antibody is a full-length antibody, a substantially intact antibody, a Fab fragment, a F(ab′)2 fragment or a single chain Fv fragment.
5. A monoclonal antibody comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein said LCVR comprises:
a) a peptide at CDRL1 with SEQ ID NO: 27,
b) a peptide at CDRL2 with SEQ ID NO: 30, and
c) a peptide at CDRL3 with SEQ ID NO: 33,
and wherein said HCVR comprises:
a) a peptide at CDRH1 with SEQ ID NO: 36
b) a peptide at CDRH2 with SEQ ID NO: 45, and
c) a peptide at CDRH3 with SEQ ID NO: 51.
6. The antibody of claim 5 , wherein the antibody is a full-length antibody, a substantially intact antibody, a Fab fragment, a F(ab′)2 fragment or a single chain Fv fragment.